Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi…
Sagtec Global Limited Strengthens Smart Property Development Collaboration Following Stateight Sdn Bhd’s Industry Recognition
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals
MK International Achieves ASEAN & Asia Records for Proprietary Quantum Molecular Technology Spray Series
American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements